Ignite Creation Date:
2024-05-05 @ 11:20 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00001249
Status:
COMPLETED
Last Update Posted:
2008-03-04
First Post:
1999-11-03
Brief Title:
Treatment of Tac-Expressing Cutaneous T-Cell Lymphoma CTCL and Adult T-Cell Leukemia ATL With Yttrium-90 Radiolabeled Anti-Tac
Sponsor:
National Cancer Institute NCI
Organization:
National Institutes of Health Clinical Center CC
Study Overview
Official Title:
Treatment of Tac-Expressing Cutaneous T-Cell Lymphoma CTCL and Adult T-Cell Leukemia ATL With Yttrium-90 Radiolabeled Anti-Tac
Status:
COMPLETED
Status Verified Date:
1999-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study purpose is to evaluate the clinical response to multidose administration of anti-Tac monoclonal antibody conjugated with 10 mCi 90Y in patients with Tac-expressing adult T-cell leukemia ATL
Detailed Description:
The study purpose is to evaluate the clinical response to multidose administration of anti-Tac monoclonal antibody conjugated with 10 mCi 90Y in patients with Tac-expressing adult T-cell leukemia ATL This study represents an extension of phase I trial Clinical Project 90-C-0043 FDA IND 3469 which permitted the administration of 5 mCi 10 mCi and 15mCi 90Y-anti-Tac to patients with ATL We propose to administer 90Y-anti-Tac 10 mCi doses to patients with Tac-expressing ATL who are over 18 years of age and who fill the patient eligibility criteria
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 90-C-0043 | None | None | None |